ASNS Research and Charts

ASNS - Arsanis Inc (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2026-02-10)

Last 0.27	Change ⇓ -0.04 (0.00%)	Volume 1,332,452
	Open 0.31	High 0.32	Low 0.26

8EMA (Daily) 0.39	40EMA (Daily) 0.94	50EMA (Daily) 1.20	STO (Daily) 33.626	MACD Hist (Daily) 0.003
8EMA (Weekly) 0.745	40EMA (Weekly) 3.97	50EMA (Weekly) 4.86	STO (Weekly) 0.937	MACD Hist (Weekly) 0.024


Company Profile
Arsanis Inc discovers and develops monoclonal antibodies for the targeted immunotherapy of serious infections. The company's monoclonal antibodies selectively focus on specific pathogens and pathogenic processes which address critical infections while minimizing the collateral damage from antimicrobial overuse, resistance, and microbiome disruption. Few of its products candidates are ASN100, for prevention of pneumonia in high risk, mechanically ventilated patients; ASN500, for prevention of respiratory Syncytial virus; ASN300 and ASN200, for prevention and treatment of bacterial infections.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.